Shares

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

By

GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) fully guaranteed new share issue with preferential rights for the Company’s existing shareholders (the “Rights Issue”), which ended on June 10, 2021, was oversubscribed. Due to the strong demand from strategic investors, a directed […]

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option Read More »

Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million

By

GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the ”Company”) Board of Directors has today, pursuant to the authorization granted by the extraordinary general meeting held on May 14, 2021 (“the EGM”), resolved on an issue of shares of a maximum of 62,524,474 shares

Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million Read More »

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

By

GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that the Board of Directors has the intention to carry out an issue of shares of approximately SEK 400 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). An extraordinary general meeting will

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million Read More »

Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million

By

GOTHENBURG, Sweden, May 7, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) Board of Directors have today, pursuant to the authorization granted by the extra general meeting on May 5, 2020, resolved on a fully guaranteed new share issue of a maximum of 42,739,736 shares with

Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million Read More »

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million

By

GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that the Board has the intention to carry out a rights issue of approximately SEK 150 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). An extraordinary general meeting will be held around

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million Read More »

Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today

By

Isofol Medical AB (publ), a clinical stage pharmaceutical company, hereby announces that the offering of newly issued shares in the Company (the “Offering”) was substantially oversubscribed. The Offering attracted strong interest among Swedish and international investors. The listing on Nasdaq First North Premier has been successful and the trading commences today.  Anders Rabbe, Managing Director,

Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today Read More »

Scroll to Top